Project overview Joint Funding
iVacALL (Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF and IFNa in children with relapsed acute lymphoblastic leukemia)
Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Essen/Dusseldorf, Heidelberg, Munich, Tubingen Entity: blood cancer Status: completed
JF-PSMA (Combined molecular and imaging-based characterization and prognostication of primary high risk prostate cancer from the multicenter 68Ga-PSMA-11 DKTK trial)
Program: ROI Funding Line: UPGRADE Project type: study-related research project Partner site: Dresden, Essen/Dusseldorf, Freiburg, Heidelberg, Munich Entity: prostate cancer Status: current
JIP (DKTK Joint Imaging Platform)
Programs: Overarching Funding Line: strategic initiative Project type: technology platform Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current
LeOPARD (Rapid liquid biopsy and intraoperative diagnostics)
Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current
MARRIAGE (Impaired DNA Repair)
Program: MTT Funding Line: UPGRADE Project type: study-related research project Partner site: Dresden, Frankfurt/Mainz, Heidelberg Entity: multiple entities Status: completed
MASTER (Cross-Entity Molecular Stratification Program for Evaluation of Individualized, Biology-Driven Therapy in Younger Adults with Advanced-Stage Cancer and Patients with Rare Tumors)
Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current
MEMORI (Imaging, molecular, and clinical features in GEJ Ca)
Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Essen/Dusseldorf, Heidelberg, Munich Entity: oesophageal cancer Status: completed
MIMETIC (Monitoring the Immune Modulating Effects in CRAFT)
Program: CI Funding Line: UPGRADE Project type: research project Partner site: Dresden, Frankfurt/Mainz, Heidelberg Entity: multiple entities Status: current
Molecular Diagnostics for Pediatric Cancers
Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: cancer in childhood and adolescence, multiple entities Status: completed
MTBA (Molecular Tumor Board Alliance)
Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: completed
MultiPro (Development of therapeutic vaccines. Multipeptide-based phase I/II clinical study for biochemically relapsed prostate carcinoma patients independent of HLA typing)
Program: CI Funding Line: INNOVATION Project type: research project Partner site: Dresden, Heidelberg, Munich, Tubingen Entity: prostate cancer Status: completed
NEO-ATT (Targeting recurrent cancer mutations by T cell therapy)
Program: CI Funding Line: INNOVATION Project type: research project Partner site: Berlin, Essen/Dusseldorf, Frankfurt/Mainz, Heidelberg Entity: multiple entities, solid tumors Status: completed
NEOLAP/SUBPAN (Subtyping of locally advanced pancreatic cancer)
Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Essen/Dusseldorf, Heidelberg, Munich Entity: pancreatic cancer Status: completed
Next Gen LOGGIC (Next generation therapies for low-grade glioma in children)
Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Essen/Dusseldorf, Freiburg, Heidelberg Entity: brain tumor, cancer in childhood and adolescence Status: completed
Next Generation Molecular Diagnostics of Malignant Gliomas
Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich Entity: brain tumor Status: completed
NonCoMs in Cancer Genomes (Identifying and Understanding Non-coding Mutations in Cancer Genome)
Program: EOM Funding Line: INNOVATION Project type: research project Partner site: Dresden, Essen/Dusseldorf, Heidelberg, Tubingen Entity: brain tumor, skin cancer Status: completed
Novel Tools for Functional Analysis of Oncogenic Pathways
Program: EOM Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: completed
NoviCARAZA (AML treatment with non-viral CAR-NK cells plus AZA)
Program: CI Funding Line: INNOVATION Project type: research project Partner site: Berlin, Frankfurt/Mainz, Freiburg, Heidelberg, Tubingen Entity: blood cancer Status: current
Overcoming therapy resistance in pancreatic cancers (Development of combinatorial therapies targeting primary and secondary drug resistance of pancreatic cancer subtypes)
Program: EOM Funding Line: INNOVATION Project type: research project Partner site: Berlin, Essen/Dusseldorf, Frankfurt/Mainz, Heidelberg, Munich Entity: pancreatic cancer Status: completed
PARADIGM (Predicting Abscopal effects after RADiotherapy and Immune-checkpoint inhibition via integrative Genomics in Melanoma)
Program: ROI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: skin cancer Status: completed
PerVision (Personalized vaccination in fusion + sarcoma patients)
Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current
PEVIDS (Personalized Tertiary Cancer Prevention)
Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Heidelberg, Munich, Tubingen Entity: colon cancer Status: current
PredictAHR (AHR signature technology as a predictor for therapy response in cancer)
Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Heidelberg, Munich Entity: multiple entities Status: current
PSMAxCD3 (PSMAxCD3 bsAb in CRPC and NSCLC)
Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Tubingen Entity: prostate cancer Status: completed
RadOncHNSCC (Radiobiological profiling for biologically stratified radiochemotherapy of HNSCC)
Program: ROI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: head and neck cancer Status: completed